Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00892073
Other study ID # 1000008879
Secondary ID 9427-H1117-120C
Status Completed
Phase Phase 2
First received April 30, 2009
Last updated November 13, 2017
Start date May 2006
Est. completion date January 2008

Study information

Verified date November 2017
Source The Hospital for Sick Children
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

To study the effect of combined diazoxide-metformin therapy on body weight in youth with hypothalamic obesity following treatment for craniopharyngioma. A secondary objective is to evaluate changes in insulin resistance (IR), beta-cell function, features of the metabolic syndrome, muscle metabolism and intramyocellular lipid.

Hypothesis: Treatment with diazoxide and metformin will result in weight loss or slowed weight gain and improved metabolic profile, compared to pretreatment levels.


Description:

46 children under the age of 22 years have been treated surgically for craniopharyngioma tumor and are currently followed at the Hospital for Sick Children, Toronto. Approximately 50% are obese (BMI ≥ 95th percentile for age and gender assessed from the updated Centre for Disease Control growth charts), all of whom have panhypopituitarism requiring hormone replacement therapy. These children are assessed regularly in Endocrine Clinic and also are invited to attend a comprehensive care clinic for evaluation by an endocrinologist (Principal Investigator), neurosurgical clinical nurse practitioner, dietitian, exercise physiologist, psychologist and social worker to provide multi-disciplinary dietary and exercise consultation and psychological counseling for weight related concerns. This clinic will provide the infrastructure for recruitment and follow-up of study patients. Recruitment of eight subjects for this pilot study will occur over 6 months from patients attending the comprehensive clinic. This number was chosen as it is equivalent to the number chosen in the pilot study of octreotide by Lustig which showed beneficial changes in body mass index with treatment.

This study evaluates a novel combination therapy in children with hypothalamic obesity at very high risk for complications. Evaluation of insulin resistance and metabolic changes on therapy will allow a better understanding of how insulin secretion relates to weight gain in this population. Successful therapy in a pilot setting will provide necessary data for a larger randomized trial in individuals with hypothalamic obesity including children with craniopharyngioma and others with damage to the hypothalamus secondary to other tumors, surgery or cranial irradiation.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date January 2008
Est. primary completion date January 2008
Accepts healthy volunteers No
Gender All
Age group 9 Years to 22 Years
Eligibility Inclusion Criteria:

- Craniopharyngioma at least one year following surgery

- Evidence of at least one other endocrinopathy of hypothalamic origin

- Stable hormone replacement therapy (with one or more of thyroxine hydrocortisone, DDAVP, sex steroids and GH)

- Obesity, defined as weight >120% Ideal Body Weight (IBW) or BMI > 27 kg/m2, with normal weight for height before tumour diagnosis and weight gain >2SD above mean for age for 1 year following tumour treatment (41).

- Age 9 -22 years

- Minimum of 6 months of standard diet and exercise intervention (run-in period). This was chosen to allow a period of prospective measurements to establish individual baseline slope of change in BMI SDS prior to initiation of active treatment with diazoxide and metformin.

Exclusion Criteria:

- Contraindications for Metformin or Diazoxide use (history or evidence of cardiac, renal, or progressive hepatic disease , diabetes or hypoxic conditions)

- Pharmacologic doses of glucocorticoids or use of other medications known to affect glucose metabolism (e.g. beta-blockers, oral hypoglycemics)

- Growth hormone (GH) initiation in the preceding 6 months or planned initiation in the next 6 months (to rule out potential confounding effect of GH on weight / body composition and glucose metabolism).

- Use of other weight loss medications

- Inability of the family and/or patient to comply with study protocol

- Non English speaking

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Diazoxide
Diazoxide will be initiated at half the dose (100 mg per day) for 2 weeks to allow the insulin sensitizing action of metformin to take effect. Dosage will be increased to 200mg daily, divided twice daily with meals for 6 months.
Metformin
Metformin will be initiated at 500 mg twice daily and increased to 1000 mg twice daily over a one week period to minimize gastrointestinal side effects. the 2000mg is to be taken with meals for 6 months.

Locations

Country Name City State
Canada The Hospital for Sick Children Toronto Ontario

Sponsors (1)

Lead Sponsor Collaborator
The Hospital for Sick Children

Country where clinical trial is conducted

Canada, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change in BMI and BMI SDS (calculated using for Disease Control formula - www.cdc.gov.doc) over 6 months of treatment compared to change in BMI and BMI SDS over 6 month 'run-in' period (prior to study start) 6 months prior to baseline, Baseline, 6 months after baseline
Secondary Insulin secretion Baseline to 6 months
Secondary Insulin resistance Baseline to 6 months
Secondary Lipid profile Baseline to 6 months
Secondary Adiponectin Baseline to 6 months
Secondary Leptin Baseline to 6 months
Secondary Features of the metabolic syndrome Baseline to 6 months
See also
  Status Clinical Trial Phase
Completed NCT02849743 - Intranasal Oxytocin in Hypothalamic Obesity Phase 2
Recruiting NCT06217848 - The Effect of GLP-1 Agonist in Patients With Hypothalamic Obesity: Prospective, Pilot Study Early Phase 1
Withdrawn NCT05147415 - Study of Tesomet With Open-label Extension in Subjects With Hypothalamic Obesity (HO) Phase 2
Not yet recruiting NCT06299891 - Efficacy and Safety of Phentermine/Topiramate in Youth With Hypothalamic Obesity Phase 2
Recruiting NCT06239116 - A Study of RM-718 in Healthy Subjects and in Patients With HO Phase 1
Completed NCT02664441 - Energy Balance & Weight Loss in Craniopharyngioma-related or Other Hypothalamic Tumors in Hypothalamic Obesity Phase 3
Completed NCT04725240 - Open-Label Study of Setmelanotide in Hypothalamic Obesity Phase 2
Completed NCT03673813 - A Personalized Program of Physical Activity and Diet for Hypothalamic Obesity
Not yet recruiting NCT06046443 - A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Phase 2
Withdrawn NCT03708913 - Neuromodulation for Hypothalamic Obesity N/A
Completed NCT01061775 - Effects of Exenatide on Hypothalamic Obesity Phase 1/Phase 2
Completed NCT02860923 - Efficacy and Safety of Exenatide in the Treatment of Hypothalamic Obesity After Craniopharyngioma Therapy Phase 3
Completed NCT00171613 - A Study of Octreotide Depot vs Saline Control in Pediatric Hypothalamic Obesity Patients Phase 4
Recruiting NCT01783717 - Effects of Exenatide on Obesity and/or Diabetes Mellitus Due to Hypothalamic Damage N/A
Enrolling by invitation NCT05774756 - A Trial of Setmelanotide in Acquired Hypothalamic Obesity Phase 3
Completed NCT05319301 - Identification and Clinical Relevance of an Oxytocin Deficient State (Melatonin Study) N/A